Nov 16 (Reuters) – The US Food and Drug Administration approved Roche’s oral treatment for certain patients with a type of advanced breast cancer, the regulator said on Monday.
The drug, giredestrant, was approved in combination with everolimus for adults with estrogen receptor-positive, HER2-negative locally advanced or metastatic cancer, whose cancer carries an ESR1 mutation and has returned or worsened during or after hormone-based treatment.
The approval was based on a late-stage study in 207 patients with ESR1-mutated tumors, in which the combination reduced the risk of disease progression or death by 62%.
The combination delayed cancer progression for a median of 10 months, compared with 5.5 months for another hormone treatment given with everolimus.
The recommended dose is 30 milligrams once daily, and the FDA also authorized a blood test to identify eligible patients.
(Reporting by Sahil Pandey in Bengaluru; Editing by Shinjini Ganguli)

